Summit Therapeutics Inc.
SMMT
$15.12
$0.251.65%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 62.76M | 62.59M | 77.63M | 103.12M | 360.42M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 220.50M | 195.21M | 224.93M | 234.21M | 568.44M |
| Operating Income | -220.50M | -195.21M | -224.93M | -234.21M | -568.44M |
| Income Before Tax | -215.70M | -189.42M | -219.17M | -231.79M | -565.71M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -215.70M | -189.42M | -219.17M | -231.79M | -565.71M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -215.70M | -189.42M | -219.17M | -231.79M | -565.71M |
| EBIT | -220.50M | -195.21M | -224.93M | -234.21M | -568.44M |
| EBITDA | -220.45M | -195.17M | -224.88M | -234.17M | -568.40M |
| EPS Basic | -0.28 | -0.24 | -0.29 | -0.31 | -0.76 |
| Normalized Basic EPS | -0.17 | -0.15 | -0.18 | -0.19 | -0.48 |
| EPS Diluted | -0.28 | -0.24 | -0.29 | -0.31 | -0.76 |
| Normalized Diluted EPS | -0.17 | -0.15 | -0.18 | -0.19 | -0.48 |
| Average Basic Shares Outstanding | 778.18M | 775.46M | 766.40M | 743.42M | 742.62M |
| Average Diluted Shares Outstanding | 778.18M | 775.46M | 766.40M | 743.42M | 742.62M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |